Symposia: Chronic Lymphocytic Leukemia: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Clinical trials, Adult, Combination therapy, Translational Research, CLL, Lymphomas, Bispecific Antibody Therapy, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune mechanism, Patient-reported outcomes, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Biological Processes, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, Clinical trials, Adult, Combination therapy, Translational Research, CLL, Lymphomas, Bispecific Antibody Therapy, Non-Hodgkin lymphoma, Clinical Research, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune mechanism, Patient-reported outcomes, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Biological Processes, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 2:45 PM-4:15 PM
Marriott Grand Ballroom 5-6
(Marriott Marquis San Diego Marina)
Moderators:
Lucrecia Yanez San Segundo, MD, PhD, Hospital Universitario Marqués de Valdecilla (IDIVAL)
and
Adam S Kittai, MD, Icahn School of Medicine at Mount Sinai
Disclosures:
Kittai: AstraZeneca: Consultancy, Research Funding, Speakers Bureau; BeiGene: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy; Abbvie: Consultancy; Eli-Lilly: Consultancy; Galapagos: Consultancy.
Immunotherapy and degraders as standalone treatment and/or in combination in relapsed/refractory CLL
2:45 PM
3:00 PM
3:15 PM
3:30 PM
3:45 PM
4:00 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH